Delivery Order SPE2DB22D2007-SPE2DB25FJ5AN
Award Date 9/17/25
Potential Completion Date 10/8/25
Potential Value $70K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a contract ceiling value of $43,178.96 under firm fixed price terms. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 16, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product used in the treatment of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 25, 2025, with a contract ceiling value of $24,038.58 and an ultimate completion date of September 16, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under DLA's procurement processes. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $63,767.62 delivery order to AmerisourceBergen Drug Corp for Ocrevus 300 mg/10 ml vials on September 8, 2025, with completion targeted for September 29, 2025. This is a firm fixed-price delivery order issued under a non-competitive set-aside arrangement. Ocrevus is a monoclonal antibody used primarily for treating multiple sclerosis, reflecting the pharmaceutical distributor's role in supplying specialized medications to support military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $72,115.74. This is a firm fixed-price delivery order with an ultimate completion date of September 15, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp will perform this work at its corporate office location in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $36,057.84 under a firm fixed-price contract structure. The order is set to be completed by September 10, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order valued at $48,077.16 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the critical role AmerisourceBergen plays in supplying...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $72,115.74. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price structure and is scheduled for completion by August 21, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...